Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp Ads (NQ: AMRN )

7.268 USD -0.032 (-0.45%)
Streaming Delayed Price Updated: 11:08 AM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Amarin Corp Ads

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke an
From GlobeNewswire News Releases
Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019. 
From Business Wire News Releases
Amarin to Participate in the Cantor Global Healthcare Conference
From GlobeNewswire News Releases
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statin
From GlobeNewswire News Releases
Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases
From GlobeNewswire News Releases
New 2019 Updates to the European Society of Cardiology’s and European Atherosclerosis Society’s Guidelines for the Management of Dyslipidaemias Incorporate Findings from the REDUCE-IT™ Cardiovascular
Clinical Practice Guidelines address how best to prevent cardiovascular events in high-risk patients with elevated triglycerides on statin treatment, among millions of people globally 
From GlobeNewswire News Releases
Amarin to Participate in the H.C. Wainwright 21st Annual Global Investment Conference
From GlobeNewswire News Releases
Amarin Provides Overview on Growing Global Attention on REDUCE-IT™ Results and Cardiovascular Risk Management Beyond Cholesterol Management
From GlobeNewswire News Releases
Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference
From GlobeNewswire News Releases
NASDAQ:AMRN Investor Notice: Investigation over Possible Securities Laws Violations by Amarin Corporation Plc
San Diego, CA -- (SBWIRE) -- 08/19/2019 -- An investigation on behalf of investors of Amarin Corporation plc (NASDAQ: AMRN) shares was announced over potential securities laws violations by Amarin... 
From SBWire - Latest Press Releases
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Non-Invasive Cellulite Treatments and Devices Dominating Billion Dollar Market
Financialnewsmedia.com News Commentary 
From PR Newswire
Amarin (AMRN) Alert: Johnson Fistel Launches Investigation into Amarin Corporation plc; Investors Encouraged to Contact Firm
Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Amarin Corporation plc ("Amarin") (NASDAQ: AMRN) for violations of federal securities laws. 
From PR Newswire
Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA
From GlobeNewswire News Releases
Amarin Reports Second Quarter 2019 Financial Results and Operational Update
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for... 
From GlobeNewswire News Releases
Amarin Announces Underwriters’ Full Exercise of Option to Purchase Additional American Depositary Shares
Amarin Corporation plc (NASDAQ:AMRN) today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares (“ADSs”), the underwriters of the... 
From GlobeNewswire News Releases
Amarin to Report Second Quarter 2019 Results and Host Conference Call on July 31, 2019
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management... 
From GlobeNewswire News Releases
Amarin Prices Public Offering of American Depositary Shares
Amarin Corporation plc (NASDAQ: AMRN) today announced the pricing of the underwritten public offering of 22,222,223 American Depositary Shares ("ADSs") at a price to the public of $18.00 per ADS. The... 
From GlobeNewswire News Releases
Amarin Announces $400,000,000 Public Offering of American Depositary Shares
Amarin Corporation plc (NASDAQ: AMRN) today announced that it has commenced an underwritten public offering of $400,000,000 of its American Depositary Shares pursuant to a shelf registration. All of... 
From GlobeNewswire News Releases
Biotech Brief: Researchers Looking at New Bundled Treatment Options for Leukemia
Financialnewsmedia.com News Commentary 
From PR Newswire
Biotech Brief: Researchers Looking at New Bundled Treatment Options For Leukemia
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thinking about trading options or stock in Apple, Amarin, BP, Cisco Systems, or Morgan Stanley?
InvestorsObserver issues critical PriceWatch Alerts for AAPL, AMRN, BP, CSCO, and MS. 
From PR Newswire
Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today provided a business update, including that the company is increasing revenue guidance... 
From GlobeNewswire News Releases
Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero,... 
From GlobeNewswire News Releases
Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero,... 
From GlobeNewswire News Releases
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual Americ
Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that three Amarin-supported posters will be presented at the American... 
From GlobeNewswire News Releases
Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero,... 
From GlobeNewswire News Releases
Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice... 
From GlobeNewswire News Releases
Amarin to Present at the Jefferies 2019 Healthcare Conference
Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero,... 
From GlobeNewswire News Releases
U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
Amarin Corporation plc (NASDAQ:AMRN) announced today that its supplemental new drug application (sNDA) for Vascepa® (icosapent ethyl) capsules has been accepted for filing and granted Priority Review... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.